1、Quality control of H1N1 influenza vaccine seed virus

2、Monitoring of Salmonella and microbial limits of influenza vaccine semiproduct

3、Evaluation on safety of domestic pandemic influenza vaccine among healthy adults in phase Ⅰ clinical trials

4、The preliminary screening of different adjuvants in transcutaneous immuniza-tion with inactivated human highly pathogenic avian influenza vaccine

5、In this study, 340 pregnant women in the third trimester were randomly assigned to receive inactivated influenza vaccine or the 23-valent pneumococcal polysaccharide vaccine (control).

6、Inactivated influenza vaccine can be given at the same time as other injectable, non-influenza vaccines, but the vaccines should be administered at different injection sites.

7、Since 1997, an influenza vaccine (FLUAD, Chiron) which contains about 10 mg of squalene per dose, has been approved in health agencies in several European countries.

8、MF59, a proprietary adjuvant containing squalene, is included in a seasonal subunit influenza vaccine licensed by the Italian regulatory authority in 1997 and subsequently by several other countries.

9、Inactivated influenza vaccine can be given at the same time as other injectable non-influenza vaccines, but the vaccines should be administered at different injection sites.

10、Vaccination continuity was assessed for subjects who were enrolled in each year from 1999 to 2002. Just 11.1% of teens received the influenza vaccine during every season during that period.

11、If the vaccine is made with the same processes as the seasonal influenza vaccine, and in the same manufacturing plant, this can be very rapid (one to two days).

12、Attesting to the feasibility of this approach, Sanofi Pasteur has played a key role in transferring influenza vaccine technology to Brazil which will be in a position to produce vaccine next year.